# Merck & Co.

**Source:** https://geo.sig.ai/brands/merck-co  
**Vertical:** Healthcare Tech  
**Subcategory:** Enterprise  
**Tier:** Leader  
**Website:** merck.com  
**Last Updated:** 2026-04-14

## Summary

Global pharma anchored by Keytruda ($25B cancer drug); $63.6B FY2024 revenue; Gardasil China collapse 2024 ($2B loss); Winrevair PAH approval 2024; Keytruda patent cliff 2028-2030 is defining challenge.

## Company Overview

Merck & Co. is one of the world's largest research-driven pharmaceutical companies, founded in the United States in 1891 as a subsidiary of the German Merck KGaA and now an independent American company headquartered in Rahway, New Jersey, trading on NYSE (MRK). The company generated approximately $63.6 billion in revenues for FY2024 under CEO Robert Davis, anchored by Keytruda (pembrolizumab)—the world's best-selling cancer drug—which generated approximately $25 billion in global sales as the dominant checkpoint inhibitor immunotherapy across over 40 approved tumor indications including lung cancer, melanoma, bladder cancer, cervical cancer, and dozens more. Merck's animal health subsidiary, Merck Animal Health, is a global leader in livestock and companion animal medicines including Bravecto (flea/tick prevention) and contributes approximately $6 billion in revenues.

Keytruda's dominance in oncology immunotherapy is the defining financial fact of modern Merck: its combination use with chemotherapy as the standard first-line treatment for many cancers creates treatment pathways that benefit Merck when any of 40+ FDA-approved indications is diagnosed. The Bristol-Myers Squibb PD-1/PD-L1 checkpoint inhibitor (Opdivo) competes directly across many of the same tumor types, while AstraZeneca's Imfinzi, Pfizer/Merck's partnership on Bavencio, and Roche's Tecentriq represent alternative checkpoint blockade options. Merck's Gardasil HPV vaccine franchise—historically a $7-8 billion annual revenue contributor—experienced a sudden revenue collapse in China in 2024 as the Chinese government shifted policy away from recommending foreign HPV vaccines, eliminating approximately $2 billion in annual China revenue.

In 2025-2026, Merck's most critical strategic challenge is the Keytruda patent expiration approaching in 2028-2030, which threatens $25+ billion in annual revenues. Merck's pipeline response includes subcutaneous Keytruda formulations (extending patent protection for formulation), Winrevair (sotatercept) for pulmonary arterial hypertension approved in 2024 targeting $4+ billion in peak sales, islatravir for HIV (partnership with Gilead), and multiple oncology combinations. The 2024 acquisition of Prometheus Biosciences for $10.8 billion adds TL1A inhibitor pipeline for inflammatory bowel disease. Merck's $15+ billion annual R&D budget and business development activities are entirely focused on filling the post-Keytruda revenue gap through 2030.

## Frequently Asked Questions

### What is Merck & Co.?
Merck & Co., Inc. (known as MSD outside the United States and Canada) is a leading global biopharmaceutical company headquartered in Rahway, New Jersey, that discovers, develops, manufactures, and markets innovative medicines and vaccines. With fiscal 2024 revenue of $64.168 billion and pharmaceutical segment revenue of $57.400 billion, Merck ranks among the world's largest pharmaceutical companies, led by Chairman and CEO Robert M. Davis.

### Who are Merck's customers and target market?
Merck serves patients globally through healthcare providers including hospitals, clinics, physicians, and pharmacies. The company's B2B customers include oncologists prescribing Keytruda for cancer treatment, primary care physicians administering Gardasil HPV vaccine, endocrinologists treating diabetes with Januvia, pulmonologists prescribing Winrevair for PAH and Ohtuvayre for COPD, and vaccination programs purchasing CAPVAXIVE pneumococcal vaccine and Enflonsia RSV preventative. Merck's medicines and vaccines reach patients in more than 140 countries worldwide.

### When was Merck founded?
Merck traces its origins to 1668 when Friedrich Jacob Merck purchased the Engel-Apotheke in Darmstadt, Germany. The American company Merck & Co. was founded in 1891 in New York City by Theodore Weicker with $200,000 from the German parent and George Merck (grandson of pharmaceutical manufacturer Emanuel Merck). Following World War I seizure and sale, Merck & Co. became an independent American company in 1919, separate from the German Merck KGaA, which is why the American company operates as MSD outside the U.S. and Canada.

### Where is Merck based?
Merck & Co. is headquartered in Rahway, New Jersey, United States. The company operates research facilities, manufacturing plants, and commercial offices globally across more than 140 countries. Merck maintains major research laboratories including Merck Research Laboratories (MRL) facilities in the United States and internationally, with manufacturing operations supporting global supply of medicines and vaccines.

### How much funding has Merck raised?
As a publicly traded Fortune 500 company (NYSE: MRK) since the early 20th century, Merck is self-funding through operations and capital markets. The company has invested over $35 billion in acquisitions since 2021 to diversify its portfolio, including Verona Pharma ($10B, 2025), Prometheus Biosciences ($10.8B, 2023), Acceleron ($11B, 2021), and Schering-Plough ($41B, 2009). Merck generates substantial operating cash flow from its $64+ billion annual revenue base, funding R&D, acquisitions, and shareholder returns through dividends and buybacks.

### What makes Merck different from competitors?
Merck differentiates through Keytruda, the world's #1 pharmaceutical product ($29.5B in 2024 sales, 18% growth); leadership in vaccines with Gardasil HPV vaccine and new launches CAPVAXIVE (pneumococcal) and Enflonsia (RSV); robust pipeline of 20+ programs predicted to generate $35+ billion by the mid-2030s; strategic acquisitions totaling $35B+ since 2021 (Verona, Prometheus, Acceleron); oncology pipeline expected to exceed $20B value by mid-2030s; commitment to scientific excellence spanning over 130 years; and proven ability to discover, develop, and commercialize breakthrough therapies addressing unmet medical needs.

### Who are Merck's main competitors?
Merck leads the pharmaceutical industry with $64.17 billion in FY2024 revenue, followed by Pfizer ($63.63B), Johnson & Johnson pharma division ($57.07B), AbbVie ($56.33B), and AstraZeneca ($54.07B). In oncology, competitors include Bristol-Myers Squibb, Roche, and Novartis. In vaccines, competitors include Pfizer, GSK, and Sanofi. The U.S. pharmaceutical market is projected to reach $979.25 billion by 2033 from $638.86 billion in 2024 (4.86% CAGR), driving intense competition across therapeutic areas.

### How can I contact Merck?
Healthcare professionals can contact Merck through www.merck.com for product information and medical inquiries, reach out to medical science liaisons for clinical support, or contact sales representatives for commercial discussions. Patients can access information about Merck medicines and vaccines through the website or patient assistance programs. Investors can access information at investorrelations.merck.com or contact investor relations. Media inquiries should be directed to the corporate communications team.

### Is Merck hiring?
Yes, Merck regularly hires across its global workforce in research and development, manufacturing, commercial operations, medical affairs, regulatory, clinical development, IT, finance, and corporate functions. The company offers comprehensive benefits including world-class health insurance, defined benefit pension and 401(k) with company matching, flexible work arrangements (global hybrid model), fitness and wellness resources, mentoring and leadership development, tuition assistance, and Employee Stock Purchase Plan. Visit jobs.merck.com for opportunities. Merck earned Fortune 100 Best Companies to Work For (2023) and Forbes 2023 World's Best Employer recognition.

### What's the latest news about Merck?
Recent developments include: completion of Verona Pharma acquisition for $10B gaining COPD drug Ohtuvayre (October 2025); FDA approval of Enflonsia RSV preventative (June 2025); announcement of 20+ pipeline programs with $50B potential and oncology pipeline exceeding $20B by mid-2030s (February 2025); fiscal 2024 results showing $64.2B revenue with Keytruda growing 18% to $29.5B; suspension of Gardasil shipments to China (February 2025-mid-2025); FDA approval of Keytruda Qlex subcutaneous formulation (September 2025); and PHA Culture of Health and Wellbeing 2025 Award.

### What is Merck's market position?
Merck leads the pharmaceutical industry with $64.17 billion in FY2024 revenue (7% growth), ranking #1 globally ahead of Pfizer ($63.63B), Johnson & Johnson pharma ($57.07B), AbbVie ($56.33B), and AstraZeneca ($54.07B). Keytruda is the world's best-selling drug ($29.5B, 46% of Merck sales). The company has market capitalization exceeding $200 billion and maintains leadership positions in oncology immunotherapy, HPV vaccination, and emerging areas like PAH (Winrevair), COPD (Ohtuvayre), and pneumococcal vaccines (CAPVAXIVE).

### What are Merck's future plans?
Merck's strategic priorities include: achieving fiscal 2025 revenue of $64-65.6B with 7-9% organic growth excluding Gardasil China and FX impacts; preparing for Keytruda patent expiration in 2028 through pipeline diversification; commercializing recently acquired assets (Ohtuvayre from Verona, Prometheus IBD pipeline); advancing 20+ pipeline programs expected to generate $35+ billion by mid-2030s with oncology alone exceeding $20B; expanding Keytruda into earlier-stage cancer indications; growing new launches (Winrevair, CAPVAXIVE, Enflonsia); and pursuing additional strategic business development transactions to strengthen long-term competitive position in high-value therapeutic areas.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*